Following the recent CE approval of the Solia S lead for left bundle branch area pacing (LBBAP), Biotronik has announced the first complete conduction system pacing (CSP) system, now fully CE-approved for LBBAP.
The Biotronik CSP system comprises three components: Selectra 3D catheters, Solia S leads, and the Amvia pacemaker family.
Francesco Zanon of Santa Maria della Misericordia Hospital (Rovigo, Italy), who earlier this month implanted the world’s first fully approved CSP system in a male patient suffering from sinus node disease (SND) and paroxysmal atrioventricular block (AVB), with moderately reduced ejection fraction (EF), said: “I am really satisfied with the usability and performance of Biotronik’s CSP system. I am empowered to deliver superior clinical treatments to my patients using a practical and easy-to-use system that is completely dedicated to LBBAP.”
LBBAP, utilising the heart’s natural conduction system efficiency, is recognised as the preferred approach to physiologic pacing.
“By introducing the world’s first approved and complete CSP system, we are revolutionising cardiac rhythm care while leading the CSP field. Biotronik is listening to clinicians’ needs, ensuring continuous advancement for the benefit of our patients and healthcare providers,” stated Alexander Uhl, CEO at Biotronik.
Biotronik’s CSP Solution will be showcased at the European Heart Rhythm Association (EHRA) congress (7–9 April, Berlin, Germany).
